Avenue Therapeutics Inc (ATXI)
2.075
-0.24
(-10.56%)
USD |
NASDAQ |
Oct 04, 16:00
2.09
+0.02
(+0.72%)
After-Hours: 20:00
Avenue Therapeutics SG&A Expense (Annual): 4.179M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.179M |
| December 31, 2022 | 5.345M |
| December 31, 2021 | 2.484M |
| December 31, 2020 | 2.347M |
| Date | Value |
|---|---|
| December 31, 2019 | 3.071M |
| December 31, 2018 | 4.12M |
| December 31, 2017 | 3.62M |
| December 31, 2016 | 0.997M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
2.347M
Minimum
2020
5.345M
Maximum
2022
3.485M
Average
3.071M
Median
2019
SG&A Expense (Annual) Benchmarks
| Fortress Biotech Inc | 94.12M |
| Checkpoint Therapeutics Inc | 8.685M |
| Journey Medical Corp | 43.91M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 12.27M |